Literature DB >> 34811887

Group I PAKs in myelin formation and repair of the central nervous system: what, when, and how.

Yan Wang1, Fuzheng Guo1.   

Abstract

p21-activated kinases (PAKs) are a family of cell division control protein 42/ras-related C3 botulinum toxin substrate 1 (Cdc42/Rac1)-activated serine/threonine kinases. Group I PAKs (PAK1-3) have distinct activation mechanisms from group II PAKs (PAK4-6) and are the focus of this review. In transformed cancer cells, PAKs regulate a variety of cellular processes and molecular pathways which are also important for myelin formation and repair in the central nervous system (CNS). De novo mutations in group I PAKs are frequently seen in children with neurodevelopmental defects and white matter anomalies. Group I PAKs regulate virtually every aspect of neuronal development and function. Yet their functions in CNS myelination and remyelination remain incompletely defined. Herein, we highlight the current understanding of PAKs in regulating cellular and molecular pathways and discuss the status of PAK-regulated pathways in oligodendrocyte development. We point out outstanding questions and future directions in the research field of group I PAKs and oligodendrocyte development.
© 2021 Cambridge Philosophical Society.

Entities:  

Keywords:  demyelination; differentiation; multiple sclerosis (MS); myelination; oligodendrocyte progenitor cells (OPCs); oligodendrocytes (OLs); p21-activated kinases (PAKs); remyelination

Mesh:

Substances:

Year:  2021        PMID: 34811887      PMCID: PMC8917091          DOI: 10.1111/brv.12815

Source DB:  PubMed          Journal:  Biol Rev Camb Philos Soc        ISSN: 0006-3231


  174 in total

1.  A new constitutively active brain PAK3 isoform displays modified specificities toward Rac and Cdc42 GTPases.

Authors:  Veronique Rousseau; Olivier Goupille; Nathalie Morin; Jean-Vianney Barnier
Journal:  J Biol Chem       Date:  2002-12-02       Impact factor: 5.157

2.  Specific functions for ERK/MAPK signaling during PNS development.

Authors:  Jason M Newbern; Xiaoyan Li; Sarah E Shoemaker; Jiang Zhou; Jian Zhong; Yaohong Wu; Daniel Bonder; Steven Hollenback; Giovanni Coppola; Daniel H Geschwind; Gary E Landreth; William D Snider
Journal:  Neuron       Date:  2011-01-13       Impact factor: 17.173

3.  White Matter Hyperintensities on Magnetic Resonance Imaging: What Is a Clinician to Do?

Authors:  José G Merino
Journal:  Mayo Clin Proc       Date:  2019-03       Impact factor: 7.616

4.  Conditional ablation of raptor or rictor has differential impact on oligodendrocyte differentiation and CNS myelination.

Authors:  Kathryn K Bercury; JinXiang Dai; Hilary H Sachs; Jared T Ahrendsen; Teresa L Wood; Wendy B Macklin
Journal:  J Neurosci       Date:  2014-03-26       Impact factor: 6.167

Review 5.  Dynamics and mechanisms of CNS myelination.

Authors:  Kathryn K Bercury; Wendy B Macklin
Journal:  Dev Cell       Date:  2015-02-23       Impact factor: 12.270

6.  Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology.

Authors:  T Rashid; M Banerjee; M Nikolic
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

7.  Sustained activation of ERK1/2 MAPK in oligodendrocytes and schwann cells enhances myelin growth and stimulates oligodendrocyte progenitor expansion.

Authors:  Akihiro Ishii; Miki Furusho; Rashmi Bansal
Journal:  J Neurosci       Date:  2013-01-02       Impact factor: 6.167

8.  Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination.

Authors:  Mark F Stidworthy; Stephane Genoud; Wen-Wu Li; Dino P Leone; Ned Mantei; Ueli Suter; Robin J M Franklin
Journal:  Brain       Date:  2004-08-02       Impact factor: 13.501

9.  Synergistic Activation of ERα by Estrogen and Prolactin in Breast Cancer Cells Requires Tyrosyl Phosphorylation of PAK1.

Authors:  Peter Oladimeji; Rebekah Skerl; Courtney Rusch; Maria Diakonova
Journal:  Cancer Res       Date:  2016-03-04       Impact factor: 12.701

10.  Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.

Authors:  Bridget M Dolan; Sergio G Duron; David A Campbell; Benedikt Vollrath; B S Shankaranarayana Rao; Hui-Yeon Ko; Gregory G Lin; Arvind Govindarajan; Se-Young Choi; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.